Alice Dragomir

Prof. Alice Dragomir

Department of Surgery, Division of Urology, Faculty of Medicine, McGill University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
JHJason Hu
Jason Hu
AAArmen G Aprikian
Armen G Aprikian
MVMarie Vanhuyse
Marie Vanhuyse
Alice DragomirAlice Dragomir
Alice Dragomir

1 October 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
Alice DragomirAlice Dragomir
Alice Dragomir
SNSara Nazha
Sara Nazha
LWLori A. Wood
Lori A. Wood
RRRicardo A. Rendon
Ricardo A. Rendon
AFAntonio Finelli
Antonio Finelli
STSimon Tanguay
Simon Tanguay

1 July 2014 in Urology
Verified
Journal Article
Closed access
MEMohamed A. Elkoushy
Mohamed A. Elkoushy
AYAlice X. Yu
Alice X. Yu
RTRoger Tabah
Roger Tabah
RPRichard J. Payne
Richard J. Payne
Alice DragomirAlice Dragomir
Alice Dragomir
SASero Andonian
Sero Andonian

1 February 2023 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
Alice DragomirAlice Dragomir
Alice Dragomir
NTNawar Touma
Nawar Touma
JHJason Hu
Jason Hu
SPSylvie Perreault
Sylvie Perreault
AAArmen G. Aprikian
Armen G. Aprikian
Background: Controversy exists regarding the risk of cardiovascular disease (CVD) associated with androgen deprivation therapy (ADT) in patients with prostate cancer. We sought to evaluate the association between gonadotropin-releasing hormone (GnRH) agonists versus GnRH antagonist and the risk of CVD in patients with prostate cancer with or without prior CVD. Patients and Methods: Using administrative databases from Quebec, Canada, we identified first-time GnRH agonists and antagonist (degarelix) users between January 2012 and June 2016. Follow-up ended at the earliest of the following: first CVD event (myocardial infarction [MI], stroke, ischemic heart disease [IHD], arrhythmia, and heart failure [HF]); switch of GnRH group; death; or December 31, 2016. Inverse probability of treatment weighting (IPTW) based on the propensity score was used to control for potential confounding. IPTW-Cox proportional hazards model accounting for competing risks was used to evaluate the association of interest. Results: Among 10,785 patients identified, 10,201 and 584 were on GnRH agonists and antagonist, respectively. Median age was 75 years (interquartile range, 69–81 years) for both groups. A total of 4,152 (40.7%) men in the GnRH agonists group and 281 (48.1%) men in the GnRH antagonist group had CVD in the 3-year period prior to ADT initiation. Risk of HF was decreased in the antagonist group compared with the GnRH agonist group among patients with prior CVD (hazard ratio [HR], 0.46; 95% CI, 0.26–0.79). Risk of IHD was decreased in the antagonist group in patients without prior CVD (HR, 0.26; 95% CI, 0.11–0.65). Use of antagonist was associated with an increased risk of arrhythmia among patients with no prior CVD (HR, 2.34; 95% CI, 1.63–3.36). Conclusions: Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.

1 December 2018 in Current Oncology
Verified
Journal Article
Open access
PDF file
SNS. Nazha
S. Nazha
STS. Tanguay
S. Tanguay
Anil KapoorAnil Kapoor
Anil Kapoor
MJM. Jewett
M. Jewett
CKC. Kollmannsberger
C. Kollmannsberger
Alice DragomirAlice Dragomir
Alice Dragomir
Introduction Outside of randomized controlled clinical trials, the understanding of the effectiveness and costs associated with targeted therapies for metastatic renal cell carcinoma (mrcc) is limited in Canada. The purpose of the present study was to use real-world prospective data to assess the effectiveness and cost of targeted therapies for patients with mrcc. Methods The Canadian Kidney Cancer Information System, a pan-Canadian database, was used to identify prospectively collected data relating to patients with mrcc. First- and subsequent-line time to treatment termination (ttt) was determined from therapy initiation time (sunitinib or pazopanib) to discontinuation of therapy. Kaplan–Meier survival curves were used to estimate the unadjusted and adjusted overall survival (os) by treatment. Unit treatment cost was used to estimate the cost by line of treatment and the total cost of therapy for the management of patients with mrcc. Results The study included 475 patients receiving sunitinib or pazopanib in the first-line setting. Patients were treated mostly with sunitinib (81%); 19% of patients were treated with pazopanib. The median ttt in the first line was 7.7 months for patients receiving sunitinib and 4.6 months for those receiving pazopanib (p < 0.001). The adjusted os was 32 months with sunitinib and 21 months with pazopanib (hazard ratio: 1.61; p < 0.01). The total median cost of first- and second-line treatments was $56,476 (interquartile range: $23,738–$130,447) for patients in the sunitinib group and $46,251 (interquartile range: $28,167–$91,394) for those in the pazopanib group. Conclusions For the two therapies, os differed significantly, with a higher median os being observed in the sunitinib group. The cost of treatment was higher in the sunitinib group, which is to be expected with longer survival.

1 November 2022 in European Urology Focus
Verified
Journal Article
Closed access
Alice DragomirAlice Dragomir
Alice Dragomir
SNSara Nazha
Sara Nazha
STSimon Tanguay
Simon Tanguay
RBRodney H. Breau
Rodney H. Breau
BBBimal Bhindi
Bimal Bhindi
LWLori A. Wood
Lori A. Wood